Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, extension study for patients with IPF who complete a
qualifying InterMune clinical trial of pirfenidone. The purpose of this study is to obtain
additional safety data for pirfenidone 2403 mg/day in patients with IPF who complete a
qualifying InterMune clinical trial of pirfenidone.